A discussion paper from the US Food and Drug Administration poses 20 questions to stakeholders for early input in 11 areas of consideration on its plans to develop a regulatory framework for distributed drug manufacturing, including manufacturing at the point of care.
The initiative could play an important role in facilitating a transformation from a highly globalized industry to one that’s far more localized
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?